UGT1A3: A Drug Target / Disease Biomarker (G54659)

Target Name: UGT1A3

NCBI ID: G54659

UGT1A3

UGT1A3: A Drug Target / Disease Biomarker

UGT1A3 is a gene that encodes a protein known as UGT1A3. UGT1A3 is a member of the UGT family of enzymes that are involved in the detoxification of xenobiotics, such as drugs, toxins, and other harmful substances that are present in the body. UGT1A3 is primarily expressed in the liver and other organs, and it is responsible for metabolizing a wide variety of compounds, including drugs and other substances that are harmful to the body.

One of the key functions of UGT1A3 is its ability to transport drugs from the liver to the plasma. This is accomplished through a process called transport, which involves the binding of the drug to the UGT1A3 enzyme. Once bound, the drug is then transported from the liver to the plasma, where it can be distributed throughout the body and carried to the target organ or site of action.

UGT1A3 is also involved in the metabolism of many other drugs, including some statins, anticancer agents, and other substances that are used to treat a wide range of medical conditions. For example, UGT1A3 is often used to metabolize the chemotherapy drug doxorubicin, which is used to treat various types of cancer.

In addition to its role in drug metabolism, UGT1A3 is also involved in the regulation of many cellular processes that are important for maintaining the health and function of the body. For example, UGT1A3 is involved in the production of certain proteins that are involved in the development and maintenance of blood vessels, as well as in the regulation of the immune system.

Based on these findings, UGT1A3 is a drug target (or biomarker) that has significant potential for the development of new treatments for a wide range of medical conditions. For example, UGT1A3 has been shown to be involved in the metabolism of many drugs that are used to treat various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia.

In addition, UGT1A3 has also been shown to be involved in the development of certain types of cancer, including liver cancer. By targeting UGT1A3 with drugs or other therapeutic agents, researchers may be able to inhibit its activity and reduce the growth of cancer cells.

Overall, UGT1A3 is a gene that has the potential to be a valuable drug target or biomarker for the development of new treatments for a wide range of medical conditions. Further research is needed to fully understand its role and to develop effective therapies that can harness its activity.

Protein Name: UDP Glucuronosyltransferase Family 1 Member A3

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:15472229, PubMed:18674515, PubMed:18719240, PubMed:23756265, PubMed:23288867, PubMed:24641623). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:23756265). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol and estrone (PubMed:15472229, PubMed:18719240, PubMed:23288867). Contributes to bile acid (BA) detoxification by catalyzing the glucuronidation of BA substrates, which are natural detergents for dietary lipids absorption (PubMed:23756265). Involved in the glucuronidation of calcidiol, which is the major circulating form of vitamin D3, essential for the regulation of calcium and phosphate homeostasis (PubMed:24641623). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonists losartan, candesartan and zolarsartan, which can inhibit the effect of angiotensin II (PubMed:18674515)

The "UGT1A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT1A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets